Compare Adaptive Biotechnologies Corp (ADPT) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Yum China Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.15 (market cap $3.33B), while Yum China Holdings Inc trades at $42.86 (market cap $14.58B). The key difference: Yum China Holdings Inc is far larger — about 4.4× Adaptive Biotechnologies Corp's market cap, and Yum China Holdings Inc pays a 2.75% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | YUMC | |
|---|---|---|
Market Cap | $3.33B | $14.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $57.95 |
52-Week Low | $10.24 | $40.18 |
Enterprise Value | $3.19B | $15.47B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
YUMC trades at $42.22, up 1.25% today, with a bullish technical signal despite mixed moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.87 exceeding the $0.854 estimate. Revenue grew to $11.80B in 2025, and the stock trades at a P/E of 16.28. Recent news highlights YUMC's acquisition of Pizza Hut brand rights in mainland China and a $512 million share repurchase plan.
The outlook is positive given consistent earnings outperformance, strategic brand control expansion, and shareholder returns. Risks include China's competitive consumer market and economic sensitivity. Analyst consensus is strongly bullish with 14 buys and no sells, supporting a favorable investment case for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
